Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature

Summary

There is considerable variability in bleeding patterns of severe haemophilia (<1% factor VIII). Knowledge of the contribution of thrombophilic factors in these patterns may improve individually tailored treatment strategies. We reviewed the literature regarding the relation between prothrombotic factors and clinical phenotype of severe haemophilia. Medline and EMBASE were searched for relevant articles. 9369 articles published between 1963 and September 2003 were screened and seven relevant papers were retrieved. Each of these reported on a different combination of thrombophilic factors. Presence of the factor V Leiden mutation appears to decrease the severity of severe haemophilia most consistently. Findings on other thrombophilic factors were inconclusive. There is a clear need for additional research on potential determinants of phenotypes of severe haemophilia before such knowledge can be translated into individual care for severe haemophilia patients with confidence.

Keywords

Severe haemophilia - phenotype - prothrombotic factors

• References

• 1 Pollmann H, Richter H, Ringkamp H. et al. When are children diagnosed as having severe haemophilia and when do they start to bleed?. A 10-year single-centre PUP study. Eur J Pediatr 1999; 158 (Suppl. 03) S166-S170.
• 2 Ramgren O. Haemophilia in Sweden III. Symptomatology, with special reference to differences between haemophilia A and B. Acta Med Scand 1962; 171: 237-242.
• 3 Rainsford SG, Hall A. A three-year study of adolescent boys suffering from haemophilia and allied disorders. Br J Haematol 1973; 539-551.
• 4 Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-399.
• 5 Molho P, Rolland N, Lebrun T. et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France The French Study Group. Haemophilia 2000; 06: 23-32.
• 6 Astermark J, Petrini P, Tengborn L. et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-1113.
• 7 Fischer K, van der Bom JG, Prejs R. et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia 2001; 07: 544-550.
• 8 Lee DH, Walker IR, Teitel J. et al. Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia A. Thromb Haemost 2000; 83: 387-391.
• 9 Nichols WC, Amano K, Cacheris PM. et al. Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood 1996; 88: 1183-1187.
• 10 Arbini AA, Mannucci PM, Bauer KA. Low prevalence of the factor V Leiden mutation among “severe” hemophiliacs with a “milder” bleeding diathesis. Thromb Haemost 1995; 74: 1255-1258.
• 11 Petkova R, Chakarov S, Horvath A. et al. Coexistence of a common prothrombotic risk factor and hemophilia in the Bulgarian hemophilic population: genotype/phenotype correlations. Balkan J Med Genet 2001; 04: 37-39.
• 12 Escuriola EC, Halimeh S, Kurnik K. et al. Symptomatic onset of severe hemophilia A in childhood is dependent on the presence of prothrombotic risk factors. Thromb Haemost 2001; 85: 218-220.
• 13 Ghosh K, Shetty S, Mohanty D. Milder clinical presentation of haemophilia A with severe deficiency of factor VIII as measured by onestage assay. Haemophilia 2001; 07: 9-12.
• 14 Nowak-Göttl U, Escuriola C, Kurnik K. et al. Haemophilia and thrombophilia What do we learn about combined inheritance of both genetic variations?. Hamostaseologie 2003; 23: 36-40.
• 15 Grünewald M, Grunewald A, Griesshammer M. Paradoxical hyperfibrinolysis is associated with a more intensely haemorrhagic phenotype in severe congenital haemophilia. Haemophilia 2002; 08: 768-775.
• 16 Tizzano EF, Soria JM, Coll I. et al. The prothrombin 20210A allele influences clinical manifestations of hemophilia A in patients with intron 22 inversion and without inhibitors. Haematologica 2002; 87: 279-285.
• 17 Ahmed R, Kannan M, Choudhry VP. et al. Does the MTHFR 677T allele alter the clinical phenotype in severe haemophilia A?. Thromb Res 2003; 109: 71-72.
• 18 Vezendi K, Tapai K, Erdodi E. et al. Thrombophilic markers in patients with congenital bleeding disorders. Haematologia 2002; 32: 467-473.
• 19 Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90: 1004-1008.
• 20 Dahlback B. Physiological anticoagulation Resistance to activated protein C and venous thromboembolism. J Clin Invest 1994; 94: 923-927.
• 21 Poort SR, Rosendaal FR, Reitsma PH. et al. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
• 22 Boushey CJ, Beresford SA, Omenn GS. et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057.
• 23 Kang SS, Zhou J, Wong PW. et al. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-421.
• 24 Frosst P, Blom HJ, Milos R. et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
• 25 Kluijtmans LA, van den Heuvel LP, Boers GH. et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
• 26 Kluijtmans LA, den Heijer M, Reitsma PH. et al. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost 1998; 79: 254-258.
• 27 Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001; 135: 367-373.
• 28 Wielders S, Mukherjee M, Michiels J. et al. The routine determination of the endogenous thrombin potential, first results in different forms of hyper and hypocoagulability. Thromb Haemost 1997; 77: 629-636.
• 29 Siegemund T, Petros S, Siegemund A. et al. Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. Thromb Haemost 2003; 90: 781-786.
• 30 Thompson SG, Kienast J, Pyke SD. et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-641.
• 31 Jastrzebska M, Torbus-Lisiecka B, Honczarenko K. et al. Von Willebrand factor, fibrinogen and other risk factors of thrombosis in patients with a history of cerebrovascular ischemic stroke and their children. Nutr Metab Cardiovasc Dis 2002; 12: 132-140.
• 32 Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-355.
• 33 Blann AD, McCollum CN. von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis. Blood Coagul Fibrinolysis 1999; 10: 375-380.
• 34 Mosnier LO, Lisman T, van den Berg HM. et al. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001; 86: 1035-1039.
• 35 Ridker PM, Hennekens CH, Lindpaintner K. et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917.
• 36 Koster T, Rosendaal FR, de Ronde H. et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-1506.
• 37 Bertina RM, Koeleman BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
• 38 Souto JC, Coll I, Llobet D. et al. The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost 1998; 80: 366-369.
• 39 van der Put NM, Steegers-Theunissen RP, Frosst P. et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995; 346: 1070-1071.
• 40 Jacques PF, Bostom AG, Williams RR. et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
• 41 Fischer K, van der Bom JG, Mauser-Bunschoten EP. et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 2001; 07: 446-452.
• 42 Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop 1980; 153-159.
• 43 Tuddenham EG, Schwaab R, Seehafer J. et al. Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. Nucleic Acids Res 1994; 22: 3511-3533.
• 44 Ingerslev J, Poulsen LH, Sorensen B. Phenotypic variation in real-time whole blood clot formation profiles in severe hemophilia. Response patterns following ex vivo addition of rFVIII and rFIX [abstract]. J Thromb Haemost. 2003: P0658.
• 45 Hooiveld M. Blood-induced cartilage damage: From mechanisms to arthropathy [dissertation]. University Medical Center Utrecht. 2003
• 46 Heijnen L, Mauser-Bunschoten EP, Roosendaal G. Participation in sports by Dutch persons with haemophilia. Haemophilia 2000; 06: 537-546.